A pharmacokinetic comparison of intravenous versus intra-arterial folinic acid. by Anderson, J. H. et al.
Br. J. Cancer (1992), 65, 133 135 t~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ Macmillan PressLtd., 1992~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
A pharmacokinetic comparison of intravenous versus intra-arterial folinic
acid
J.H. Anderson', D.J. Kerr2, A. Setanoians2, T.G. Cooke' & C.S. McArdle'
'University Department ofSurgery, The Royal Infirmary, Glasgow G31 2ER; 2CRC Department ofMedical Oncology, Glasgow
University, Glasgow G61 IBD, UK.
Summary Recent clinical trials have suggested that a combination of folinic acid and 5-fluorouracil (5-FU)
may improve response rates and survival in patients with advanced colorectal cancer. However, this regimen
has been complicated by potentially life threatening toxicity. Regional delivery of folinic acid via a hepatic
artery catheter might be expected to reduce systemic exposure and subsequent adverse effects.
The present study compared the pharmacokinetic profiles of intravenous and intra-hepatic arterial infusions
of folinic acid in patients with colorectal liver metastases (n = 6) who were being treated with weekly regional
infusions of 5-FU. The mean area under the plasma concentration - time curve, the peak plasma concentra-
tion and the steady state volume of distribution were 163 jig ml-' h-' (SD 41), 18.5 jg ml-' (SD 1.2) and
7.41 m-2 (SD 0.44) respectively following intravenous administration of folinic acid compared with
142jigml- h-' (SD45), 14.8tjgml-' (SD2.4) and 11.21m2 (SD 1.22) following intra-hepatic arterial
administration (P <0.05). Regional folinic acid was therefore associated with a statistically significant
reduction in systemic exposure compared with the intravenous route.
The outlook for patients with colorectal liver metastases
remains depressing; the mean survival for patients in the
West of Scotland is approximately 3 months (Wood et al.,
1976). The results of systemic chemotherapy have been disap-
pointing. Average response rates of only 10-15% have been
reported following treatment with 5-FU and response has not
been accompanied by increased survival (Kemeny, 1983).
These reports have lead to a third of surgeons in England
and Wales opting not to actively treat patients with non-
resectable colorectal liver metastases (Karanjia et al., 1990)
and trials in the UK continue to include 'no active treatment'
control arms (Hunt et al., 1990).
Recent studies, however, have suggested that the addition
of folinic acid may significantly improve survival amongst
advanced colorectal cancer patients receiving 5-FU (Erlich-
man, 1988, Poon et al., 1989; Kerr, 1989). Briefly, folinic acid
enhances 5-FU activity by stabilising the binding of the 5-FU
metabolite, fluorodeoxyuridine monophosphate, to the
enzyme thymidylate synthase. Unfortunately, therapy has
been complicated by systemic toxicity which can be
occasionally life-threatening.
The rationale for regional chemotherapy is the delivery of
high drug concentrations to the compartment harbouring the
tumour with relatively less drug escaping into the systemic
vascular compartment. There is a large literature on intra-
hepatic arterial administration of 5-FU and FUdR to
patients with hepatic metastases from colorectal primary
cancers. In summary, the data are suggestive that tumour
response rates are higher comparing regional with systemic
administration, but there is no convincing evidence that
intra-arterial chemotherapy significantly prolongs survival.
The aim of the present study was to compare the pharma-
cokinetic profiles of intravenous and intra-hepatic arterial
folinic acid in patients who were receiving a 24 h infusion of
5-FU via an indwelling hepatic artery catheter.
Patients and methods
Patients
Patients with biopsy-proven, metastatic, colorectal adenocar-
cinoma, confined to the liver were recruited. All subjects had
previously undergone a resection of an adenocarcinoma of
the colon or rectum and surgical placement of a hepatic
artery catheter (Infusaport 38940. Shiley Infusaid Inc., Nor-
wood, MA, USA). Entry criteria were; WHO performance
status <2, life expectancy >2 months, white cell count
>4 x 1091-' platelets > 150 x 1091'- and bilirubin
<30timol 1-'. Pre-treatment staging consisted of physical
examination, abdominal CT scan and chest radiograph. All
patients gave informed consent prior to entering the study.
Treatment
Patients received a 24 h arterial infusion of 5-FU,
600 mg m-2 per week, for 6 consecutive weeks. On the fourth
and sixth weeks of this regimen, folinic acid (100 mgm-2)
was administered as a 2 h infusion. On one occasion the
folinic acid was given intravenously and on the other
occasion it was administered via the hepatic artery. 5-FU and
folinic acid infusions were commenced simultaneously. The
order of the route of folinic acid delivery was random.
Pharmacokinetic assessments
Five ml of peripheral venous blood was sampled before each
folinic acid infusion and at 1, 2, 2.25, 2.5, 3, 4, 5, 6, 8, 14 and
26 h after commencement of the infusion. Blood was placed
in tubes containing lithium heparin which were stored in ice.
With minimal delay (less than 5 min) the blood was centri-
fuged at 5,000 r.p.m. for 5 min then the plasma was removed
and stored at - 20°C in light protected vials.
As folinic acid has the propensity to be oxidised, control
experiments were performed, spiking blood samples with
known quantities of folinic acid, to ensure that plasma
folates were stable during collection and separation. Folinic
acid degradation was always less than 10% under these
conditions.
Serum levels of folinic acid were assayed using a sensitive
and specific HPLC assay system (inter and intra-assay
coefficients of variation <5%) with a limit of detection of
50 ng ml-'. A C18 microbondapack (10 microns) column is
used. The mobile phase consists of two components. Mobile
phase A; 0.25 M phosphate buffer (pH 5); Mobile phase B,
50% 0.25 M phosphate buffer (pH 5), 50% methanol. The
mobile phase consists of phase A throughout with a 50%
contribution from phase B between 10-15 min run time. The
extraction method depends on the addition of cold methanol
to plasma (1.5:1 vol/vol) and subsequent vortex evaporation
of the supernate prior to redissolution and injection onto the
column in H20. Detection was performed by UV analysis at
310 nm.
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Plasma levels of folinic acid were plotted against time and
the data were fitted to an infusional compartment open
model, by the method of least squares, using an 'in house'
computer programme based on the Marquhardt algorithm.
The area under the plasma concentration-time curve was
extrapolated to infinity. Peak concentrations were actual end
of infusion concentrations and the volume of distribution
was computed from the pharmacokinetic model parameters
(A, a, B, 13) corrected for duration of infusion.
Statistical methods
The data were analysed using the paired student's t-test.
Results
Patients
Six patients entered the study (four males, two females).
Mean age was 61 years (range 39-75). Three patients had
previous treatment for their metastases (two with mitomycin
C and one with regional 9'Y-glass microspheres) but their
disease had progressed despite these therapies.
Pharmacokinetics
The pharmacokinetic parameters for folinic acid are sum-
marised in Table I. The plasma profiles for patient 1 are
shown in Figure 1. The mean area under the time/concen-
tration curve was 163 igml-'h (SD41) following
intravenous administration of folinic acid and 142 tLgml-
1 h
(SD 45) following the arterial route (P <0.02). The mean
peak plasma concentration was 18.5 jig ml (SD 1.2) fol-
lowing intravenous administration and 14.8 fig ml-' (SD 2.4)
with the arterial route (P = 0.02). The mean volume of distri-
bution at steady state was 7.42 1 m-2 (SD 0.44) following
intravenous administration and 11.2 1 m-2 (SD 1.22) with the
arterial route (P = 0.028). There was no significant difference
for clearance, tla or tip of folinic acid comparing intra-
venous and regional delivery.
Toxicity
No patients exhibited any evidence of treatment related toxi-
city. In particular, there were no signs of myelosuppression,
liver failure, diarrhoea, stomatitis or vomiting. Subsequent to
completion of the pharmacokinetic study, three patients, who
received further intra-arterial infusions of folinic acid,
experienced occlusion of their hepatic artery catheter.
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Figure 1 Plasma profile for patient 1. -O , IA, * -, IV.
Discussion
Regional infusion of 5-FU reduces systemic exposure to the
drug and therefore diminishes systemic toxicity (Goldberg et
al., 1990). Our attempts, in the present study, to apply these
principles to folinic acid administration have revealed a
statistically significant regional advantage for the arterial
route. The pharmacokinetic parameters following intra-
venous administration of folinic acid are similar to those
described in previous studies (Straw et al., 1984; McGuire et
al., 1988; Trave et al., 1988; Rustum, 1989).
Intra-arterial infusion of folinic acid reduces the plasma
AUC and end of infusion plasma concentration and increases
its volume of distribution relative to intravenous administra-
tion. We are not sure why the volume of distribution is
greater following loco-regional infusion but it is possible that
this could be due to increased first pass folinic acid extraction
by the liver. We plan to clarify this point by measuring drug
concentrations in tumours and normal liver biopsies taken
during peroperative folinic acid infusions.
There was a trend towards prolongation of drug half-life
following arterial infusion, but this did not reach significance.
Folinic acid is cleared predominantly by the liver by meta-
bolism to 5 methyl tetrahydrofolate, however it was not
Table I Comparison of pharmacokinetic parameters for folinic acid following
intravenous or intra-hepatic arterial administration
Patient
1 2 3 4 5 6 Mean SE
Area under curve IV 100 132 210 166 179 191 163 16.6
(gml'h-') IA 69 115 203 156 161 148 142 18.5
Peak concentration IV 18.7 17.5 19.2 17.3 18.1 20.4 18.5 0.5
(jzgmlh') IA 11.7 12.5 16.8 16.9 16.9 13.9 14.8 0.9
Clearance IV 1.0 0.76 0.48 0.6 0.56 0.52 0.65 0.08
(1 h-' m-2) IA 1.44 0.87 0.49 0.64 0.62 0.68 0.79 0.13
Steady state volume IV 6.1 7.6 6.7 9.2 7.0 7.9 7.4 0.44
of distribution IA 12.3 16.2 10.8 9.2 7.4 11.1 11.2 1.22
(I m-2)
ta IV 0.3 0.1 0.2 0.6 1.5 0.5 0.53 0.21
(h) IA 0.7 2.9 5.3 1.2 0.5 2.3 2.15 0.74
t1, IV 4.8 7.9 14.9 17.3 11.0 16.4 12.1 2.05
(h) IA 7.5 32.0 36.7 16.5 10.7 20.1 20.7 5.81
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possible to measure this metabolite in the present study. The
regional advantage conferred by hepatic arterial of folinic
acid can be assessed by the ratio of plasma AUC's or end of
infusion peak plasma concentrations; the larger the ratio, the
greater the regional advantage (AUCi,: AUCia = 1.15,
Cpiv:Cpia= 1.25). The regional advantage conferred by hepatic
arterial infusion of folinic acid is relatively small compared to
drugs such as 5-fluorouracil (Goldberg et al., 1990).
Although there is an apparent pharmacokinetic advantage,
this is offset by the potential for catheter thrombosis. In our
experience, which includes placement of hepatic artery
catheters in more than 70 patients, 5-FU can be infused
regionally without complications. However, the addition of
regional folinic acid to this treatment regimen has been
associated with catheter occlusion in three out of six patients
so treated. This information is anecdotal and has not been
the subject of a formal study but we believe that it is
important to supply these data. There was no other apparent
treatment related toxicity.
Clinically, there are two strategies to try to overcome the
problem of systemic relapse following loco-regional therapy:
combination of regional with systemic therapy or dose
escalating the regional therapy until peripheral venous con-
centrations equal those which are achieved with conventional
systemic treatment. We have decided to adopt the latter
approach and we are currently undertaking a phase I trial of
intravenous folinic acid in combination with a 24 h intra-
hepatic arterial infusion of 5-FU. The folinic acid schedule
has been fixed and the dose of 5-FU will escalated until
plasma concentrations are similar to those achieved with
intravenous infusions. This should allow the generation of
high levels within the liver, the site of predominant bulk
disease, but maintain adequate systemic levels.
We thank Mrs J. Simpson and Mrs H. Wotherspoon for assistance
with this study.
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